About Pulmokine
Pulmokine is a Healthcare company based in Rensselaer (United States) founded in 2007 by Larry Zisman, and was acquired by XOMA Corporation in December 2024. Treatments for pulmonary hypertension are developed using kinase technology. Pulmokine has raised $1 million across 3 funding rounds from investors including NIH, HHS and XOMA Corporation. Its chief executive, as recorded, is Larry Zisman. Pulmokine offers products and services including Breathing Aid Products. Its focus areas include Life Sciences, Pulmonology, Drugs and Pulmonary Arterial Hypertension. Its competitors include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals; 2 of its 3 listed competitors have raised funding.
Company details
Pulmokine is a pharmaceutical company focused on pulmonary disease and kinase technology. Primary indications targeted are pulmonary arterial hypertension and related disorders such as pulmonary arterial fibrosisinterstitial lung disease, sarcoidosis and lung cancer. It has an exclusive license from Gilead to develop a portfolio of PDGFR inhibitors for PAH (currently in pre-clinical phase). Future research areas include ACE2 inhibitors for PAH and a novel class of kinase inhibitors.
- Headquarters Rensselaer, United States
- Founders Larry Zisman
- Stage Acquired
- SectorsHealthcare
- Website pulmokine.net
- Acquired by XOMA Corporation (Dec 2024)
- Total Equity Funding$1M (USD)
in 3 rounds
- Latest Funding Round$1M (USD), Series A
Mar 2015
- InvestorsNIH
& 3 more
- Acquired byXOMA Corporation
(Dec 2024)
Products & Services of Pulmokine
Pulmokine offers a comprehensive portfolio of products and services, including Breathing Aid Products.
Products designed to support easier breathing and respiratory health.
Funding Insights of Pulmokine
Pulmokine has successfully raised a total of $1M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1M
- Total Rounds 3
- Last Round Series A — $1M
- First Round $311,629
(Jul 2010)
- Investors Count 3
All 3 funding rounds of Pulmokine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $1M | Series A | – | – | |
| Jan 2013 | Grant | – | – | ||
| Jul 2010 | $311,629 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Pulmokine
Pulmokine has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and XOMA Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed-stage life sciences investments are made in the US. | broadviewventures.org | Boston, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Antibody-based therapeutics are developed for endocrine and metabolic diseases. | 1981 | xoma.com | Berkeley, United States |
Investor details for Pulmokine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pulmokine
5 people are tracked at Pulmokine (2 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Larry Zisman | Founder & CEO | Leadership |
Ron Wolff | VP, Affairs & Toxicology | Leadership |
Aaron Waxman | Scientific Advisor | Board & advisors |
Rubin Tuder | Scientific Advisor | Board & advisors |
Shreefal Mehta | Co-Founder & Executive Chair | Board & advisors |
Complete people profiles for Pulmokine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pulmokine
4 dated milestones of Pulmokine across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Pulmokine is founded.
- Funding First funding round of $312K.
- Funding Latest funding round, Series A, of $1.0M.
- Exit Acquired by XOMA Corporation.
Competitors of Pulmokine
Pulmokine has 3 listed competitors in our database, 2 of them funded. They include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aerovatetx.com | 2018 | Boston, United States | $75.82M | 31 | Therapeutic solutions for pulmonary arterial hypertension are developed. | |
| vivus.com | 1991 | Mountain View, United States | 59 | Developer of therapeutic solutions for obesity and sexual health | ||
| centessa.com | 2021 | Boston, United States | $250M | 83 | Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed. |
Detailed competitors of Pulmokine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as Pulmokine (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pulmokine
Complete news archive for Pulmokine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pulmokine
Pulmokine was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Pulmokine is headquartered in Rensselaer, United States. It is registered at Rensselaer, New York, United States.
Larry Zisman is the CEO of Pulmokine, as recorded in our data. They have also founded this company.
Pulmokine is a funded company, having raised a total of $1M across 3 funding rounds to date. The company's 1st funding round was a Grant of $311.63K, raised on Jul 2010.
Pulmokine is a pharmaceutical company focused on pulmonary disease and kinase technology. Primary indications targeted are pulmonary arterial hypertension and related disorders such as pulmonary arterial fibrosisinterstitial lung disease, sarcoidosis and lung cancer. It has an exclusive license from Gilead to develop a portfolio of PDGFR inhibitors for PAH (currently in pre-clinical phase). Future research areas include ACE2 inhibitors for PAH and a novel class of kinase inhibitors.
Pulmokine's top competitors include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals.
Pulmokine offers Breathing Aid Products.
Pulmokine has 4 investors. Key investors include NIH, HHS, XOMA Corporation, and Broadview Ventures.
Yes. Pulmokine was acquired by XOMA Corporation in December 2024.